NCT01631253

Brief Summary

The purpose of this study is to investigate the impact on ovarian reserve after single- port, two-port, or four-port access laparoscopic ovarian cyst enucleation based on serum anti mullerian hormone change.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2011

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2011

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 26, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 29, 2012

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
Last Updated

July 3, 2012

Status Verified

June 1, 2012

Enrollment Period

1.4 years

First QC Date

June 26, 2012

Last Update Submit

June 30, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Preoperative and postoperative changes in anti-mullerian hormone level

    The primary outcome of our study is the impact on ovarian reserve determined by AMH after the application of the three laparoscopic techniques for the treatment of ovarian cyst.In all study patients, at preoperation and 1 week, 1 month, 3 month after operation, AMH is serially measured.

    preoperative, postoperative at 1week, 1 and 3 months

Secondary Outcomes (1)

  • postoperative pain scores

Study Arms (3)

single-port access laparoscopic ovarian cyst enucleation

ACTIVE COMPARATOR

Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)

Procedure: Laparoscopic ovarian cyst enucleation

two-port laparoscopic access ovarian cyst enucleation

ACTIVE COMPARATOR

Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.

Procedure: Laparoscopic ovarian cyst enucleation

four-port access laparoscopic ovarian cyst enucleation

ACTIVE COMPARATOR

Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.

Procedure: Laparoscopic ovarian cyst enucleation

Interventions

four-port access laparoscopic ovarian cyst enucleationsingle-port access laparoscopic ovarian cyst enucleationtwo-port laparoscopic access ovarian cyst enucleation

Eligibility Criteria

Age21 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 21-45 years Ultrasound
  • CT, MRI diagnosis as ovarian cyst , need to cyst enucleation
  • Size of cyst : between 3cm and 10cm
  • Regular menstrual cycles defined as cycle length between 25 and 35 days
  • Agreement to be enrolled in the study.

You may not qualify if:

  • Previous ovarian surgery
  • suspicious of malignancy
  • Postmenopause
  • Use of oral contraceptive drug, GnRH agonist /antagonist, or other drugs related with ovarian function in last 3 months
  • Known endocrine disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gangnam CHA medical center

Seoul, Gamnamgu, South Korea

RECRUITING

Related Publications (1)

  • Yoon BS, Kim YS, Seong SJ, Song T, Kim ML, Kim MK, Paek JY. Impact on ovarian reserve after laparoscopic ovarian cystectomy with reduced port number: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2014 May;176:34-8. doi: 10.1016/j.ejogrb.2014.02.025. Epub 2014 Feb 20.

MeSH Terms

Conditions

Ovarian Cysts

Condition Hierarchy (Ancestors)

CystsNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesGonadal DisordersEndocrine System Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 26, 2012

First Posted

June 29, 2012

Study Start

October 1, 2011

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

July 3, 2012

Record last verified: 2012-06

Locations